Hecht JR, Park YS, Tabernero J, Lee MA, et al. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet 2025 Oct 20:S0140-6736(25)02025-2. doi: 10.1016/S0140-6736(25)02025.
PMID: 41130252